Study of EC0489 for the Treatment of Refractory or Metastatic Tumors
NCT00852189
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
65
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer
Interventions
DRUG:
EC0489, Injection
DRUG:
EC20
DRUG:
EC0489, Injection
Sponsor
Endocyte